Donor Lymphocyte Infusion to Enhance the Graft-versus-Myeloma Effect

Donor lymphocyte infusion (DLI) has the potential to significantly deepen response after allogeneic stem cell transplantation (ASCT) in multiple myeloma (MM). Subsequently, DLI offers opportunity for long-term progression-free and, most importantly, overall survival patients with MM. application is a complex procedure, whereby many factors need be considered (e.g., patient-oriented prior application, disease-specific factors, as well possible combinations further therapies during and DLI). There are two settings which can given, they follows: salvage option progressive disease or prophylactic setting MM resolved response. While first studies used setting, results appear associated better prolonged outcomes. Furthermore, (both salvage) given earlier ASCT (3–6 months) The incorporation of novel agents showed similar responses DLI. However, updated larger evaluations urgently needed determine specific role variables such treatment environment an ever-evolving field This review underlines rationale ASCT, settings, patterns progression DLI, avenues enhance graft-versus-myeloma effect exerted by